



A Leading Global Health Care Group

Credit Suisse – Global Health Care Conference, March 4, 2015



For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

Frankfurt stock exchange (DAX30): FRE
US ADR program (OTC): FSNUY

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius Group: Sales and Net Income Reach All-Time Highs

Sales

€bn


CAGR 12%



Net Income¹

€m


CAGR 21%



¹ Before special items


Fresenius Group: Dividend Development and Total Shareholder Return

22nd consecutive dividend increase



Dividend growth aligned to EPS growth
Pay-out ratio: 22%

Total Return: Fresenius outperforms index



Compounded annual total return
Dec 31, 2004 – Dec 31, 2014

¹ Proposal 1993-2013 stock split-adjusted; 2013 pre split: €1.25





Source: Bloomberg; dividends reinvested

Fresenius Group: Financial Results

		Q4/14	FY/14
Sales		€6,520 m	€23,231 m
	Growth cc	20%	16%
	Growth actual rates	23%	14%
EBIT¹		€935 m	€3,158 m
	Growth cc	7%	4%
	Growth actual rates	11%	4%
Net income¹		€318 m	€1,086 m
	Growth cc	5%	4%
	Growth actual rates	7%	3%

¹ Before one-time items

Fresenius Group: Financial Results by Business Segment


		Q4/14	Growth Q4 YoY	FY/14	Growth FY YoY
	Sales	US\$4,320 m	12%	US\$15,832 m	8%
	EBIT	US\$663 m	0%	US\$2,255 m	0%
	Sales	€1,386 m	11%	€5,146 m	3%
	EBIT	€239 m	3%	€873 m	-6%
	Sales	€1,361 m	59%	€5,244 m	55%
	EBIT	€156 m	44%	€553 m	42%
	Sales	€387 m	6%	€1,042 m	2%
	EBIT	€32 m	7%	€59 m	7%

Fresenius Kabi: 2015 Regional Growth Prospects

North America

-3% to +3% organic sales growth

- ↑ Launches – expect at least top end of 6 – 10 target range (backloaded)
- ↓ Further easing of I.V. drug shortages
- ↓ Lower sales from products imported under regulatory discretion



Regional Sales Distribution

Europe

3% to 5% organic sales growth

- ↑ Demand for clinical nutrition
- Stable HES (blood volume substitute) sales

Emerging Markets

~10 % organic sales growth

- ↑ Product roll-outs, e.g. clinical nutrition, medical devices
- ↑ Double-digit growth in China
- Mid to high single-digit growth in Asia-Pacific ex China

Fresenius Kabi: Efficiency Program Initiated

Program designed to maintain cost leadership and increase profitability

- Increase efficiency in production
- Streamline administrative structures
- Implementation costs: ~€100 million in 2015; 50% cash-effective
- Geographic split: Europe 2/3, Asia-Pacific/Latin America/Africa 1/3
- Full annual savings run rate of ~€40 million by 2018, initial savings of ~€10 million in 2015, linear build-up

Fresenius Kabi: New Mid-Term Expectations



5% - 8% Sales Growth
organic

6% - 10% EBIT Growth
constant currency



Growth Drivers

Growing Markets

- €29 bn global market; 4% growth
- Consolidation driven by higher quality standards

Attractive Product Pipeline

- 120 I.V. drug launch projects worldwide
- Regional product roll-outs, e.g. clinical nutrition in U.S. and emerging markets

Strong Emerging Markets Presence

- Long-standing presence, local production and cost structures
- China largest market; ~€550m 2014 sales; expect to grow at double-digit rates

Fresenius Helios: Integration Fully on Track

- Operating business in great shape:
 - 4% organic sales growth
 - ~€1.8 bn sales contribution from acquired hospitals in 2014; EBIT margin increased to 8.8%

- Integration fully on track, below cost budget:


	Target	2014	2015e
Synergies clinic level	➔ ~€85 m p.a. straight-line build-up between now and spring 2016	~40%	~60% (H1/2016)
Integration cost	➔ lower end of ~€60-80 m range	~€50 m	~€10 m

- Mid-term EBIT margin target of 12 – 15% (upper half) in line with HELIOS' hospital development plan

Fresenius Helios: Best Positioned in German Acute Care Market

**German acute care market
€87 bn**

**Largest network
110 hospitals**




- ~29.100 acute care beds
- ~1.2 million inpatient admissions
- ~3.0 million outpatient admissions

**HELIOS is the leading hospital operator
Market share: ~6%**

Fresenius Vamed: Expanded and Diversified Geographic Presence



- Project delays in Russia/Ukraine leading to flat organic sales growth
- €1.7 bn German university hospital project (construction, 30-year technical management contract) on track, started in Q4
- Expanded geographic presence – entry into seven local markets – 3% contribution to 2014 project sales
- €840 million 2014 order intake (+13%) in project business, diversified regional split:



German university hospital: 50:50 contract VAMED and consortium partner

Credit Suisse – Global Health Care Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, March 4, 2015

Sustained Double-Digit Sales and EBIT Growth



Fresenius Group: 2015 Financial Outlook by Business Segment

Fresenius Kabi	Sales growth <small>organic</small> EBIT growth <small>constant currency</small>	3% – 5% 4% – 6%
Fresenius Helios	Sales growth <small>organic</small> Sales growth <small>reported</small> EBIT	3% – 5% 6% – 9% €630 – 650 m
Fresenius Vamed	Sales growth <small>organic</small> EBIT growth	single digit % 5% – 10%

Fresenius Group: 2015 Financial Outlook

Revenue growth
at constant currency

7% – 10%


Net income growth¹
at constant currency

9% – 12%

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs (hospitals of Rhön-Klinikum AG ~€10 million before tax), before costs for efficiency program at Fresenius Kabi (~€100 million before tax) and gain from the divestment of two HELIOS hospitals (€34 million before tax); 2014 before special items

Fresenius Group: Confirming 2017 Target / Exceeding Target at Current FX Rates

~€30 billion Sales; €1.4 to €1.5 billion Net Income



Attachments



Fresenius Group: Profit and Loss Statement

€m	Q4/14	Growth Q4 YoY		FY/14	Growth FY YoY	
		actual rates	constant rates		actual rates	constant rates
Sales	6,520	23%	20%	23,231	14%	16%
EBIT ¹	935	11%	7%	3,158	4%	4%
Net interest	-171	-27%	-22%	-602	-3%	-4%
Income taxes	-196	-5%	0%	-725	-6%	-7%
Net income ²	318	7%	5%	1,086	3%	4%

¹ 2014 before integration costs (Fenwal – Q4: €44 m / FY: €50 m; acquired Rhön hospitals – Q4: €39 m / FY: €51 m) and disposal gains (two HELIOS hospitals – Q4: n.a. / FY: €22 m; Rhön Stake – Q4: n.a. / FY: €35 m); 2013 before integration costs (Fenwal – Q4: €20 m; FY: €54 m)

² Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before integration costs (Fenwal Q4: €29 m / FY: €33 m; acquired Rhön hospitals Q4: €32 m / FY: €41 m) and disposal gains (two HELIOS hospitals – Q4: n.a. / FY: €21 m; Rhön Stake – Q4: n.a. / FY: €34 m); 2013 before integration costs (Fenwal – Q4: €14 m; FY: €40 m)

Fresenius Kabi: Strong Organic Sales Growth in Q4

€m	Q4/14	Organic Growth Q4 YoY	FY/14	Organic Growth FY YoY
Infusion Therapy	253	5%	977	3%
I.V. Drugs	500	11%	1,813	4%
Clinical Nutrition	364	7%	1,384	7%
Medical Devices/ Transfusion Technology	268	3%	972	3%
Total sales	1,386	7%	5,146	4%

Fresenius Kabi: Strong Organic Sales Growth in Q4

€m	Q4/14	Organic Growth Q4 YoY	FY/14	Organic Growth FY YoY
Europe	564	7%	2,102	3%
North America	413	6%	1,531	1%
Asia-Pacific	264	5%	987	7%
Latin America/Africa	145	15%	526	14%
Total sales	1,386	7%	5,146	4%

Fresenius Kabi: EBIT Margin Fully in Line with Guidance

€m	Q4/14	Growth Q4 YoY	FY/14	Growth FY YoY
Europe Margin	118 20.9%	16% 160 bps	345 16.4%	-3% -100 bps
North America Margin	138 33.4%	18% 130 bps	557 36.4%	2% 50 bps
Asia-Pacific/Latin America/Africa Margin	59 14.4%	7% -80 bps	239 15.8%	2% -70 bps
Corporate and Corporate R&D	-76	-77%	-268	-26%
Total EBIT Margin	239 17.2%	3% 0% cc -120 bps	873 17.0%	-6% -4% cc -150 bps

EBIT excluding integration costs (Fenwal – Q4: €44 million / FY: €50 million)

Fresenius Helios: Sales and EBIT Growth Driven by First-Time Consolidation of Rhön Hospitals

€m	Q4/14	Growth Q4 YoY	FY/14	Growth FY YoY
Total sales	1,361	59%	5,244	55%
EBIT				
Established clinic portfolio	108	7%	395	5%
Margin	12.4%	20 bps	11.4%	0 bps
Acquisitions / Divestitures (consolidation / deconsolidation <1 yr)	48		158	
Margin	9.8%		8.8%	
Total EBIT	156	44%	553	42%
Margin	11.5%	-120 bps	10.5%	-100 bps

Before integration costs (acquired Rhön hospitals: €51 million) and disposal gains (two HELIOS hospitals: €22 million; Rhön stake: €35 million)

Fresenius Helios: Performance Indicators

	2014	2013	Change
No. of hospitals	110	74	49%
- Acute care clinics	86	51	68%
- Post-acute care clinics	24	23	4%
No. of beds	34,188	23,502	45%
- Acute care clinics	29,068	18,885	54%
- Post-acute care clinics	5,120	4,617	11%
Admissions			
- Acute care (inpatient)	1,148,473	754,703	52%
Occupancy			
- Post-acute care	83%	83%	
Average length of stay (days)			
- Acute care	6.6	6.6	
- Post-acute care	26.5	26.5	
Bad debt in % of sales	0.3%	0.2%	

Fresenius Helios: 2014 Clinic Development Plan

	Years in Portfolio								Total ¹
	<1	1	2	3	4 ¹	5	6	>6	
No. of clinics	-	-	12	3	40	-	6	49	110
Revenue (€m)	-	-	401	160	1,799	-	205	2,515	5,080
Target									
EBIT margin (%)	-	2.0	4.0	6.0	8.0	10.0	12.0	12.0-15.0	
EBIT (€m)	-	-	16.0	9.6	143.9	-	24.6	301.8	495.9
Reported									
EBIT margin (%)	-	-	8.1	4.8	7.9	-	8.8	13.5	10.6
EBIT (€m)	-	-	32.4	7.7	141.2	-	18.0	338.3	537.6
No. of clinics > target	-	-	8	1	19	-	2	22	52
No. of clinics < target	-	-	4	2	21	-	4	27	58

¹ includes all hospitals acquired from Rhön Klinikum, €29 m integration costs allocated to individual hospitals.


Fresenius Vamed: Sales and EBIT in Line with Expectations

€m	Q4/14	Growth Q4 YoY	FY/14	Growth FY YoY
Project business	252	0%	558	-4%
Service business	135	17%	484	11%
<hr/> Total sales	387	6%	1,042	2%
Total EBIT	32	7%	59	7%
Margin	8.3%	10 bps	5.7%	30 bps
Order intake ¹	162	n.a.	840	13%
Order backlog ¹			1,398	23%

¹ Project business only

Fresenius Group: Leverage Ratio

Net debt/EBITDA (at annual average FX rates for both EBITDA and net debt)



¹ Before integration costs and disposal gains (two Helios hospitals; Rhön stake)





² Pro forma including Rhön hospitals and FME acquisitions, excluding two Helios hospitals

³ Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG; before special items






⁴ Before special items; without major acquisitions

⁵ Pro forma acquisitions; before special items

Fresenius Group: Consistent Cash Generation and Proven Track Record of Deleveraging

CFFO margin

FCF margin (before acquisitions & dividends)

Capex in % of sales

Net Debt / EBITDA


Cash Flow Development 2014

€m	Operating CF		Capex (net)		Free Cash Flow ¹	
	FY/14	Margin	FY/14	Margin	FY/14	Margin
	641	12.5%	-352	-6.9%	289	5.6%
	558	10.6%	-263	-5.0%	295	5.6% ³
	-9	-0.9%	-9	-0.8%	-18	-1.7%
Corporate/ Other	-6	n.a.	-7	n.a.	-13	n.a.
 FRESENIUS excl. FMC	1,184	11.0% ²	-631	-5.5%	553	5.5% ²
 FRESENIUS Group	2,585	11.1%	-1,323	-5.7%	1,262	5.4%

¹ Before acquisitions and dividends

² Margin incl. FMC dividend

³ Understated: 6.8% excluding €62 million of capex commitments from acquisitions

Margin = in % of sales

Share Information

Share key facts

Number of shares ¹	541,532,600
WKN / ISIN	578560 / DE0005785604
Ticker symbol	FRE
Bloomberg symbol	FRE GR
Reuters symbol	FREG.de

ADR key facts

Ratio	4 ADRs = 1 ordinary share
ADR CUSIP / ISIN	35804M105 / US35804M1053
Ticker symbol	FSNUY
Exchange	OTCQX International Premier
Structure	Sponsored Level I ADR
Depository bank	Deutsche Bank

¹ As of December 31, 2014

Financial Calendar 2015

30.04.2015	Report on 1 st quarter 2015
20.05.2015	Annual General Meeting, Frankfurt/Main
30.07.2015	Report on 2 nd quarter 2015
29.10.2015	Report on 3 rd quarter 2015

Please note that these dates could be subject to change.

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA

Telephone: +49 6172 608-2485

e-mail: Birgit.Grund@fresenius.com

For further information and current news: <http://www.fresenius.com>